SOLID TUMOURS:@0.084848:0.038601:0.266058:0.038601:0.266058:0.019343:0.084848:0.019343:0.011712:0.020438:0.010866:0.005315:0.017498:0.006515:0.010019:0.015405:0.021613:0.020438:0.015405:0.014276:0.011712
76:@0.023705:0.038809:0.044778:0.038809:0.044778:0.019212:0.023705:0.019212:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
REFERENCES:@0.084242:0.093226:0.195079:0.093226:0.195079:0.077192:0.084242:0.077192:0.011161:0.010006:0.009236:0.010006:0.011161:0.010006:0.014239:0.015009:0.010006:0.010006
1.:@0.084242:0.110346:0.098456:0.110346:0.098456:0.096341:0.084242:0.096341:0.009476:0.004738
 American Cancer Society. Cancer facts:@0.120589:0.110346:0.475163:0.110346:0.475163:0.096341:0.120589:0.096341:0.000000:0.012657:0.016044:0.011118:0.005148:0.003421:0.011067:0.011682:0.010434:0.010177:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.010177:0.008518:0.011203:0.011067:0.003421:0.011118:0.005798:0.009168:0.004738:0.010177:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.010177:0.005371:0.011682:0.011067:0.005798:0.006636
and  figures  2018.  American  Cancer  Soci-:@0.120589:0.124845:0.475154:0.124845:0.475154:0.110840:0.120589:0.110840:0.011682:0.010434:0.011716:0.004738:0.003301:0.004165:0.004165:0.011511:0.010399:0.005078:0.011118:0.006636:0.004738:0.003305:0.009476:0.009476:0.009476:0.009489:0.004738:0.004738:0.003303:0.012657:0.016044:0.011118:0.005148:0.003421:0.011067:0.011682:0.010434:0.004738:0.003296:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.003298:0.008518:0.011203:0.011067:0.003421:0.005679
ety. Available  at  https://www.cancer.org/:@0.120589:0.139344:0.475139:0.139344:0.475139:0.125339:0.120589:0.125339:0.011118:0.005798:0.009168:0.004738:0.007406:0.011400:0.009476:0.011682:0.003421:0.003421:0.011682:0.011665:0.003421:0.011118:0.004738:0.002684:0.011682:0.005798:0.004738:0.002668:0.010434:0.005798:0.005798:0.011665:0.006636:0.004738:0.007475:0.007475:0.014214:0.014214:0.014214:0.004738:0.011067:0.011682:0.010434:0.011067:0.011118:0.003886:0.004738:0.011203:0.005148:0.011511:0.007475
content/dam/cancer-org/research/can-:@0.120589:0.153844:0.460851:0.153844:0.460851:0.139838:0.120589:0.139838:0.011067:0.011203:0.010434:0.005798:0.011118:0.010434:0.005798:0.007475:0.011716:0.011682:0.016044:0.007475:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.005679:0.011203:0.005140:0.011511:0.007475:0.005075:0.011118:0.006636:0.011118:0.011682:0.005030:0.011067:0.010434:0.007475:0.011067:0.011682:0.010434:0.005679
cer-facts-and-statistics/annual-cancer-:@0.120589:0.168343:0.443639:0.168343:0.443639:0.154337:0.120589:0.154337:0.011067:0.011118:0.005148:0.005679:0.005371:0.011682:0.011067:0.005798:0.006636:0.005679:0.011682:0.010434:0.011716:0.005679:0.006636:0.005798:0.011682:0.005798:0.003421:0.006636:0.005798:0.003421:0.011067:0.006636:0.007475:0.011682:0.010434:0.010434:0.010399:0.011682:0.003421:0.005679:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.005679
facts-and-figures/2018/cancer-facts-and-:@0.120589:0.182842:0.464192:0.182842:0.464192:0.168837:0.120589:0.168837:0.005371:0.011682:0.011067:0.005798:0.006636:0.005679:0.011682:0.010434:0.011716:0.005679:0.004165:0.004165:0.011511:0.010399:0.005073:0.011118:0.006636:0.007475:0.009476:0.009476:0.009476:0.009476:0.007475:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.005679:0.005371:0.011682:0.011067:0.005798:0.006636:0.005679:0.011682:0.010434:0.011716:0.005679
figures-2018.pdf. Accessed: January 2018.:@0.120589:0.197341:0.465841:0.197341:0.465841:0.183336:0.120589:0.183336:0.004165:0.004165:0.011511:0.010399:0.005070:0.011118:0.006636:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738:0.011665:0.011716:0.005381:0.004738:0.004738:0.012657:0.011067:0.011067:0.011118:0.006636:0.006636:0.011118:0.011716:0.004738:0.004738:0.008244:0.011682:0.010434:0.010399:0.011682:0.005148:0.009168:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
2.:@0.084242:0.211840:0.098456:0.211840:0.098456:0.197835:0.084242:0.197835:0.009476:0.004738
  National Cancer Institute: Surveillance,:@0.120589:0.211840:0.475163:0.211840:0.475163:0.197835:0.120589:0.197835:0.004738:-0.004738:0.012657:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.016318:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.016318:0.003866:0.010434:0.006636:0.005798:0.003421:0.005798:0.010399:0.005798:0.011118:0.004738:0.016318:0.008518:0.010399:0.005148:0.009476:0.011118:0.003421:0.003421:0.003421:0.011682:0.010434:0.011067:0.011118:0.004738
Epidemiology, and End Results Programme:@0.120589:0.226339:0.475175:0.226339:0.475175:0.212334:0.120589:0.212334:0.009168:0.011665:0.003421:0.011716:0.011118:0.016044:0.003421:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738:0.004823:0.011682:0.010434:0.011716:0.004823:0.009168:0.010434:0.011716:0.004823:0.010382:0.011118:0.006636:0.010399:0.003421:0.005798:0.006636:0.004823:0.010126:0.005075:0.011203:0.011511:0.005148:0.011682:0.016044:0.016044:0.011118
(SEER).  https://seer.cancer.gov/statfacts/:@0.120589:0.240839:0.475152:0.240839:0.475152:0.226833:0.120589:0.226833:0.006312:0.008518:0.009168:0.009168:0.010382:0.006312:0.004738:0.004738:0.016112:0.010434:0.005798:0.005798:0.011665:0.006636:0.004738:0.007475:0.007475:0.006636:0.011118:0.011118:0.003883:0.004738:0.011067:0.011682:0.010434:0.011067:0.011118:0.003890:0.004738:0.011511:0.011203:0.009476:0.007475:0.006636:0.005798:0.011682:0.005798:0.005371:0.011682:0.011067:0.005798:0.006636:0.656927
html/melan.html. Accessed: January 2018.:@0.120589:0.255338:0.471998:0.255338:0.471998:0.241332:0.120589:0.241332:0.010434:0.005798:0.016044:0.003421:0.007475:0.016044:0.011118:0.003421:0.011682:0.010434:0.004738:0.010434:0.005798:0.016044:0.003421:0.004738:0.004738:0.012657:0.011067:0.011067:0.011118:0.006636:0.006636:0.011118:0.011716:0.004738:0.004738:0.008244:0.011682:0.010434:0.010399:0.011682:0.005148:0.009168:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
3.:@0.084242:0.269837:0.098460:0.269837:0.098460:0.255832:0.084242:0.255832:0.009479:0.004738
  Sosman  JA.  Cytotoxic  chemotherapy  for:@0.120589:0.269837:0.475163:0.269837:0.475163:0.255832:0.120589:0.255832:0.004738:-0.004738:0.008347:0.011032:0.006465:0.015873:0.011511:0.010263:0.004738:0.005969:0.008073:0.012486:0.004567:0.004738:0.005976:0.013735:0.008997:0.005627:0.011032:0.005627:0.011032:0.008039:0.003250:0.010895:0.004738:0.005975:0.010895:0.010263:0.010947:0.015873:0.011032:0.005627:0.010263:0.010947:0.004977:0.011511:0.011494:0.008997:0.004738:0.005957:0.005542:0.011374:0.005148
metastatic melanoma. :@0.120589:0.284336:0.315237:0.284336:0.315237:0.270331:0.120589:0.270331:0.016215:0.011289:0.005969:0.011853:0.006808:0.005969:0.011853:0.005969:0.003592:0.011238:0.001249:0.016215:0.011289:0.003592:0.011853:0.010605:0.011374:0.016215:0.011853:0.004909:0.004738
UpToDate:@0.311747:0.284336:0.395627:0.284336:0.395627:0.270331:0.311747:0.270331:0.011374:0.011836:0.007458:0.011374:0.012897:0.011853:0.005969:0.011118
.  https://:@0.395798:0.284336:0.475197:0.284336:0.475197:0.270331:0.395798:0.270331:0.004909:0.001249:0.001249:0.012144:0.007509:0.007509:0.013376:0.008347:0.006448:0.009185:0.007475
www.uptodate.com/contents/cyto- :@0.120589:0.298835:0.475744:0.298835:0.475744:0.284830:0.120589:0.284830:0.016095:0.016095:0.016095:0.006619:0.012281:0.013547:0.007680:0.013085:0.013598:0.013564:0.007680:0.012999:0.006619:0.012948:0.013085:0.017925:0.009356:0.012948:0.013085:0.012315:0.007680:0.012999:0.012315:0.007680:0.008518:0.009356:0.011409:0.009510:0.006140:0.011545:0.005644:0.004738
toxic-chemotherapy-for-metastatic-:@0.120589:0.313334:0.472015:0.313334:0.472015:0.299329:0.120589:0.299329:0.007167:0.012572:0.009578:0.004789:0.012435:0.007047:0.012435:0.012144:0.012828:0.017754:0.012914:0.007509:0.012144:0.012828:0.006859:0.013393:0.013376:0.011049:0.007560:0.007252:0.013085:0.007030:0.007560:0.017583:0.012657:0.007338:0.013222:0.008176:0.007338:0.013222:0.007338:0.004960:0.012606:0.005679
melanoma?source=see_link. Accessed::@0.120589:0.327834:0.475159:0.327834:0.475159:0.313828:0.120589:0.313828:0.016899:0.011973:0.004276:0.012537:0.011289:0.012059:0.016899:0.012537:0.010964:0.007492:0.012059:0.011255:0.005882:0.011922:0.011973:0.011220:0.007492:0.011973:0.011973:0.009407:0.004276:0.004276:0.011289:0.009442:0.005591:0.010861:0.012657:0.011067:0.011067:0.011118:0.006636:0.006636:0.011118:0.011716:0.004738
January 2018.:@0.120589:0.342333:0.234727:0.342333:0.234727:0.328327:0.120589:0.328327:0.008244:0.011682:0.010434:0.010399:0.011682:0.005148:0.009168:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
4.:@0.084242:0.356832:0.098456:0.356832:0.098456:0.342827:0.084242:0.342827:0.009476:0.004738
  Hodi FS, O’Day SJ, McDermott DF, :@0.120589:0.356832:0.403307:0.356832:0.403307:0.342827:0.120589:0.342827:0.004738:-0.004738:0.011682:0.011203:0.011716:0.003421:0.004738:0.008296:0.008518:0.004738:0.004738:0.014864:0.006004:0.012726:0.011682:0.009168:0.004738:0.008518:0.008244:0.004738:0.004738:0.015719:0.011067:0.012726:0.011118:0.005627:0.016044:0.011203:0.005798:0.005798:0.004738:0.012726:0.006209:0.004738:0.004738
et al:@0.403307:0.356832:0.440064:0.356832:0.440064:0.342827:0.403307:0.342827:0.011118:0.005798:0.004738:0.011682:0.003421
. Im-:@0.440064:0.356832:0.475128:0.356832:0.475128:0.342827:0.440064:0.342827:0.004738:0.004738:0.003866:0.016044:0.005679
proved survival with ipilimumab in patients:@0.120589:0.371331:0.475156:0.371331:0.475156:0.357326:0.120589:0.357326:0.011665:0.005080:0.011203:0.009476:0.011118:0.011716:0.005833:0.006636:0.010399:0.005148:0.009476:0.003421:0.009476:0.011682:0.003421:0.005845:0.014214:0.003421:0.005798:0.010434:0.005833:0.003421:0.011665:0.003421:0.003421:0.003421:0.016044:0.010399:0.016044:0.011682:0.011665:0.005848:0.003421:0.010434:0.005833:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636
with metastatic melanoma. :@0.120589:0.385830:0.356795:0.385830:0.356795:0.371825:0.120589:0.371825:0.014214:0.003421:0.005798:0.010434:0.006094:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.006096:0.016044:0.011118:0.003421:0.011682:0.010434:0.011203:0.016044:0.011682:0.004738:0.004738
N Engl J Med:@0.358152:0.385830:0.470420:0.385830:0.470420:0.371825:0.358152:0.371825:0.012657:0.006091:0.009168:0.010434:0.011511:0.003421:0.006096:0.008244:0.006093:0.015719:0.011118:0.011716
.:@0.470420:0.385830:0.475157:0.385830:0.475157:0.371825:0.470420:0.371825:0.004738
2010;363(8):711.:@0.120589:0.400329:0.251660:0.400329:0.251660:0.386324:0.120589:0.386324:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.004738
5.:@0.084242:0.414829:0.098456:0.414829:0.098456:0.400823:0.084242:0.400823:0.009476:0.004738
Maio M, Grob JJ, Aamdal S, :@0.120589:0.414829:0.354592:0.414829:0.354592:0.400823:0.120589:0.400823:0.015890:0.011853:0.003592:0.011374:0.003729:0.015890:0.004909:0.003729:0.015086:0.005249:0.011374:0.011836:0.003729:0.008415:0.008415:0.004909:0.003729:0.012828:0.011853:0.016215:0.011888:0.011853:0.003592:0.003729:0.008689:0.004909:0.004738
et al:@0.353583:0.414829:0.389844:0.414829:0.389844:0.400823:0.353583:0.400823:0.011289:0.005969:0.003729:0.011853:0.003421
. Five-year :@0.390015:0.414829:0.479861:0.414829:0.479861:0.400823:0.390015:0.400823:0.004909:0.003729:0.008467:0.003592:0.009647:0.011289:0.005850:0.009339:0.011289:0.011853:0.005145:0.004738
survival rates for treatment-naïve patients:@0.120589:0.429328:0.475152:0.429328:0.475152:0.415322:0.120589:0.415322:0.006808:0.010570:0.005319:0.009647:0.003592:0.009647:0.011853:0.003592:0.006267:0.005319:0.011853:0.005969:0.011289:0.006808:0.006267:0.005542:0.011374:0.005319:0.006267:0.005969:0.005248:0.011289:0.011853:0.005969:0.016215:0.011289:0.010605:0.005969:0.005850:0.010605:0.011853:0.003592:0.009647:0.011289:0.006267:0.011836:0.011853:0.005969:0.003592:0.011289:0.010605:0.005969:0.006636
with advanced melanoma who received:@0.120589:0.443827:0.475176:0.443827:0.475176:0.429822:0.120589:0.429822:0.014385:0.003592:0.005969:0.010605:0.006277:0.011853:0.011888:0.009647:0.011853:0.010605:0.011238:0.011289:0.011888:0.006277:0.016215:0.011289:0.003592:0.011853:0.010605:0.011374:0.016215:0.011853:0.006277:0.014385:0.010605:0.011374:0.006277:0.005248:0.011289:0.011238:0.011289:0.003592:0.009647:0.011289:0.011716
ipilimumab plus dacarbazine in a phase III:@0.120589:0.458326:0.475094:0.458326:0.475094:0.444321:0.120589:0.444321:0.003592:0.011836:0.003592:0.003592:0.003592:0.016215:0.010570:0.016215:0.011853:0.011836:0.004943:0.011836:0.003592:0.010570:0.006808:0.004943:0.011888:0.011853:0.011238:0.011853:0.005319:0.011836:0.011853:0.007440:0.003592:0.010605:0.011289:0.004943:0.003592:0.010605:0.004943:0.011853:0.004943:0.011836:0.010605:0.011853:0.006808:0.011289:0.004943:0.004037:0.004037:0.003866
trial. :@0.120589:0.472825:0.160562:0.472825:0.160562:0.458820:0.120589:0.458820:0.005969:0.005319:0.003592:0.011853:0.003592:0.004909:0.004738
Journal of Clinical Oncology:@0.161178:0.472825:0.402093:0.472825:0.402093:0.458820:0.161178:0.458820:0.008415:0.011374:0.010570:0.005319:0.010605:0.011853:0.003592:0.005354:0.011374:0.005542:0.005354:0.014077:0.003592:0.003592:0.010605:0.003592:0.011238:0.011853:0.003592:0.005354:0.015035:0.010605:0.011238:0.011374:0.003592:0.011374:0.011682:0.009168
. 2015;33:@0.402264:0.472825:0.475149:0.472825:0.475149:0.458820:0.402264:0.458820:0.004909:0.005354:0.009647:0.009647:0.009647:0.009647:0.004909:0.009650:0.009476
(10):1191.:@0.120589:0.487324:0.201082:0.487324:0.201082:0.473319:0.120589:0.473319:0.006483:0.009647:0.009647:0.006483:0.004909:0.009647:0.009647:0.009647:0.009647:0.004738
6.:@0.084242:0.501824:0.098456:0.501824:0.098456:0.487818:0.084242:0.487818:0.009476:0.004738
  Robert  C, Thomas L, Bondarenko I, :@0.120589:0.501824:0.426549:0.501824:0.426549:0.487818:0.120589:0.487818:0.004738:-0.004738:0.010382:0.011203:0.011665:0.011118:0.005148:0.005798:0.004738:0.003541:0.013906:0.004738:0.008296:0.007286:0.010434:0.011203:0.016044:0.011682:0.006636:0.008296:0.007902:0.004738:0.008296:0.009818:0.011203:0.010434:0.011716:0.011682:0.005077:0.011118:0.010434:0.008586:0.011203:0.008296:0.003866:0.004738:0.004738
et al:@0.430106:0.501824:0.470421:0.501824:0.470421:0.487818:0.430106:0.487818:0.011118:0.005798:0.008296:0.011682:0.003421
.:@0.470421:0.501824:0.475159:0.501824:0.475159:0.487818:0.470421:0.487818:0.004738
Ipilimumab plus dacarbazine for previously:@0.120589:0.516323:0.475133:0.516323:0.475133:0.502317:0.120589:0.502317:0.003866:0.011665:0.003421:0.003421:0.003421:0.016044:0.010399:0.016044:0.011682:0.011665:0.005164:0.011665:0.003421:0.010399:0.006636:0.005148:0.011716:0.011682:0.011067:0.011682:0.005148:0.011665:0.011682:0.007269:0.003421:0.010434:0.011118:0.005148:0.005371:0.011203:0.005148:0.005140:0.011665:0.005078:0.011118:0.009476:0.003421:0.011203:0.010399:0.006636:0.003421:0.009168
untreated metastatic melanoma. :@0.120589:0.530822:0.406112:0.530822:0.406112:0.516817:0.120589:0.516817:0.010399:0.010434:0.005798:0.005071:0.011118:0.011682:0.005798:0.011118:0.011716:0.006115:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.006123:0.016044:0.011118:0.003421:0.011682:0.010434:0.011203:0.016044:0.011682:0.004738:0.004738
N Engl J:@0.407498:0.530822:0.475169:0.530822:0.475169:0.516817:0.407498:0.516817:0.012657:0.006113:0.009168:0.010434:0.011511:0.003421:0.006123:0.008244
Med:@0.120589:0.545321:0.159142:0.545321:0.159142:0.531316:0.120589:0.531316:0.015719:0.011118:0.011716
. 2011;364(26): 2517-26.:@0.159142:0.545321:0.348009:0.545321:0.348009:0.531316:0.159142:0.531316:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
7.:@0.084242:0.559820:0.098456:0.559820:0.098456:0.545815:0.084242:0.545815:0.009476:0.004738
  Ribas A, Puzanov I, Dummer R, :@0.120589:0.559820:0.364761:0.559820:0.364761:0.545815:0.120589:0.545815:0.004738:-0.004738:0.010382:0.003421:0.011665:0.011682:0.006636:0.002497:0.012657:0.004738:0.002480:0.010126:0.010399:0.007269:0.011682:0.010434:0.011203:0.009476:0.002497:0.003866:0.004738:0.002497:0.012726:0.010399:0.016044:0.016044:0.011118:0.005148:0.002487:0.010382:0.004738:0.004738
et al:@0.362496:0.559820:0.397004:0.559820:0.397004:0.545815:0.362496:0.545815:0.011118:0.005798:0.002489:0.011682:0.003421
. Pembro- :@0.397004:0.559820:0.479887:0.559820:0.479887:0.545815:0.397004:0.545815:0.004738:0.002497:0.010126:0.011118:0.016044:0.011665:0.005075:0.011203:0.005679:0.004738
lizumab versus investigator-choice:@0.120589:0.574319:0.475163:0.574319:0.475163:0.560314:0.120589:0.560314:0.005302:0.005302:0.009151:0.012281:0.017925:0.013564:0.013547:0.011648:0.011357:0.012999:0.007030:0.008518:0.012281:0.008518:0.011648:0.005302:0.012315:0.011357:0.012999:0.008518:0.007680:0.005302:0.013393:0.013564:0.007680:0.013085:0.007030:0.007560:0.012948:0.012315:0.013085:0.005302:0.012948:0.011118
chemotherapy  for  ipilimumab-refractory:@0.120589:0.588819:0.475163:0.588819:0.475163:0.574813:0.120589:0.574813:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.010415:0.005371:0.011203:0.005148:0.004738:0.010420:0.003421:0.011665:0.003421:0.003421:0.003421:0.016044:0.010399:0.016044:0.011682:0.011665:0.005697:0.005077:0.011118:0.005371:0.005148:0.011682:0.011067:0.005798:0.011203:0.005148:0.009168
melanoma  (KEYNOTE-002): a  randomised, :@0.559983:0.094589:0.919291:0.094589:0.919291:0.080583:0.559983:0.080583:0.016044:0.011118:0.003421:0.011682:0.010434:0.011203:0.016044:0.011682:0.004738:0.002776:0.006312:0.010109:0.009168:0.010126:0.012657:0.014864:0.007286:0.009168:0.005679:0.009476:0.009476:0.009476:0.006312:0.004738:0.007526:0.011682:0.004738:0.002779:0.005148:0.011682:0.010434:0.011716:0.011203:0.016044:0.003421:0.006636:0.011118:0.011716:0.004738:0.004738
controlled, phase 2 trial. :@0.559983:0.110534:0.782997:0.110534:0.782997:0.096529:0.559983:0.096529:0.011067:0.011203:0.010434:0.005798:0.005070:0.011203:0.003421:0.003421:0.011118:0.011716:0.004738:0.011289:0.011665:0.010434:0.011682:0.006636:0.011118:0.011289:0.009476:0.011289:0.005798:0.005148:0.003421:0.011682:0.003421:0.004738:0.004738
Lancet  Oncol.:@0.789548:0.110534:0.914553:0.110534:0.914553:0.096529:0.789548:0.096529:0.007902:0.011682:0.010434:0.011067:0.011118:0.005798:0.004738:0.006541:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738
 :@0.914553:0.110534:0.919291:0.110534:0.919291:0.096529:0.914553:0.096529:0.004738
2015;16(8):908-18.:@0.559983:0.126480:0.706208:0.126480:0.706208:0.112475:0.559983:0.112475:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
8.:@0.523636:0.142425:0.537850:0.142425:0.537850:0.128420:0.523636:0.128420:0.009476:0.004738
  Weber JS, D’Angelo  SP, Minor  D, :@0.559983:0.142425:0.860274:0.142425:0.860274:0.128420:0.559983:0.128420:0.004738:-0.004738:0.015616:0.011118:0.011665:0.011118:0.005148:0.011135:0.008244:0.008518:0.004738:0.011135:0.012726:0.006004:0.012657:0.010434:0.011511:0.011118:0.003421:0.011203:0.004738:0.006385:0.008518:0.008019:0.004738:0.011135:0.015719:0.003421:0.010434:0.011203:0.005148:0.004738:0.006385:0.012726:0.004738:0.004738
et al:@0.866671:0.142425:0.909825:0.142425:0.909825:0.128420:0.866671:0.128420:0.011118:0.005798:0.011135:0.011682:0.003421
.:@0.909825:0.142425:0.914563:0.142425:0.914563:0.128420:0.909825:0.128420:0.004738
Nivolumab versus chemotherapy in pa-:@0.559983:0.158371:0.914524:0.158371:0.914524:0.144366:0.559983:0.144366:0.012657:0.003421:0.009476:0.011203:0.003421:0.010399:0.016044:0.011682:0.011665:0.011853:0.009476:0.011118:0.005148:0.006636:0.010399:0.006636:0.011853:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011650:0.009168:0.011853:0.003421:0.010434:0.011853:0.011665:0.011682:0.005679
tients  with  advanced  melanoma  who:@0.559983:0.174316:0.914546:0.174316:0.914546:0.160311:0.559983:0.160311:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.004738:0.010541:0.014214:0.003421:0.005798:0.010434:0.004738:0.010541:0.011682:0.011716:0.009476:0.011682:0.010434:0.011067:0.011118:0.011716:0.004738:0.010541:0.016044:0.011118:0.003421:0.011682:0.010434:0.011203:0.016044:0.011682:0.004738:0.010545:0.014214:0.010434:0.011203
progressed after  anti-CTLA-4  treatment:@0.559983:0.190262:0.914562:0.190262:0.914562:0.176257:0.559983:0.176257:0.011665:0.005080:0.011203:0.011511:0.005071:0.011118:0.006636:0.006636:0.011118:0.011716:0.015650:0.011682:0.005371:0.005798:0.011118:0.005148:0.004738:0.010894:0.011682:0.010434:0.005798:0.003421:0.005679:0.013906:0.007286:0.007902:0.012657:0.005679:0.009476:0.004738:0.010897:0.005798:0.005077:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798
(CheckMate 037): a randomised, con-:@0.559983:0.206208:0.914539:0.206208:0.914539:0.192202:0.559983:0.192202:0.006312:0.013906:0.010434:0.011118:0.011067:0.008586:0.015719:0.011682:0.005798:0.011118:0.013855:0.009476:0.009476:0.009476:0.006312:0.004738:0.013855:0.011682:0.013855:0.005148:0.011682:0.010434:0.011716:0.011203:0.016044:0.003421:0.006636:0.011118:0.011716:0.004738:0.013855:0.011067:0.011203:0.010434:0.005679
trolled,  open-label, phase 3 trial. :@0.559983:0.222153:0.851565:0.222153:0.851565:0.208148:0.559983:0.208148:0.005798:0.005075:0.011203:0.003421:0.003421:0.011118:0.011716:0.004738:0.004738:0.005003:0.011203:0.011665:0.011118:0.010434:0.005679:0.003421:0.011682:0.011665:0.011118:0.003421:0.004738:0.009749:0.011665:0.010434:0.011682:0.006636:0.011118:0.009749:0.009476:0.009749:0.005798:0.005148:0.003421:0.011682:0.003421:0.004738:0.004738
Lancet:@0.856556:0.222153:0.914556:0.222153:0.914556:0.208148:0.856556:0.208148:0.007902:0.011682:0.010434:0.011067:0.011118:0.005798
Oncol.:@0.559983:0.238099:0.615709:0.238099:0.615709:0.224093:0.559983:0.224093:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738
 2015;16(4):375-84.:@0.615709:0.238099:0.766672:0.238099:0.766672:0.224093:0.615709:0.224093:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
9.:@0.523636:0.254044:0.537853:0.254044:0.537853:0.240039:0.523636:0.240039:0.009479:0.004738
  Atkins MB, Kunkel L, Sznol M, :@0.559983:0.254044:0.788265:0.254044:0.788265:0.240039:0.559983:0.240039:0.004738:-0.004738:0.012486:0.005627:0.008415:0.003250:0.010263:0.006465:0.004362:0.015548:0.009647:0.004567:0.004367:0.009938:0.010228:0.010263:0.008415:0.010947:0.003250:0.004367:0.007731:0.004567:0.004368:0.008347:0.007098:0.010263:0.011032:0.003250:0.004368:0.015548:0.004567:0.004738
et al:@0.787882:0.254044:0.823755:0.254044:0.823755:0.240039:0.787882:0.240039:0.010947:0.005627:0.004367:0.011511:0.003421
. High-dose:@0.823583:0.254044:0.914551:0.254044:0.914551:0.240039:0.823583:0.240039:0.004567:0.004368:0.011511:0.003250:0.011340:0.010263:0.005508:0.011545:0.011032:0.006465:0.011118
recombinant interleukin-2 therapy in pa-:@0.559983:0.269990:0.914538:0.269990:0.914538:0.255985:0.559983:0.255985:0.004907:0.010947:0.010895:0.011032:0.015873:0.011494:0.003250:0.010263:0.011511:0.010263:0.005627:0.011563:0.003250:0.010263:0.005627:0.010947:0.004977:0.003250:0.010947:0.010228:0.008415:0.003250:0.010263:0.005508:0.009305:0.011563:0.005627:0.010263:0.010947:0.004977:0.011511:0.011494:0.008997:0.011563:0.003250:0.010263:0.011563:0.011494:0.011511:0.005679
tients with metastatic melanoma: long-term:@0.559983:0.285935:0.914550:0.285935:0.914550:0.271930:0.559983:0.271930:0.005627:0.003250:0.010947:0.010263:0.005627:0.006465:0.004396:0.014043:0.003250:0.005627:0.010263:0.004396:0.015873:0.010947:0.005627:0.011511:0.006465:0.005627:0.011511:0.005627:0.003250:0.010895:0.004396:0.015873:0.010947:0.003250:0.011511:0.010263:0.011032:0.015873:0.011511:0.004567:0.004396:0.003250:0.011032:0.010263:0.011340:0.005508:0.005627:0.010947:0.005449:0.016044
survival update. :@0.559983:0.301881:0.694287:0.301881:0.694287:0.287876:0.559983:0.287876:0.006465:0.010228:0.004977:0.009305:0.003250:0.009305:0.011511:0.003250:0.005354:0.010228:0.011494:0.011545:0.011511:0.005627:0.010947:0.004567:0.004738
Cancer Journal of Science:@0.694902:0.301881:0.914574:0.301881:0.914574:0.287876:0.694902:0.287876:0.013735:0.011511:0.010263:0.010895:0.010947:0.004977:0.005354:0.008073:0.011032:0.010228:0.004977:0.010263:0.011511:0.003250:0.005354:0.011032:0.005200:0.005354:0.008347:0.010895:0.003250:0.010947:0.010263:0.010895:0.011118
of America:@0.559983:0.317826:0.650893:0.317826:0.650893:0.303821:0.559983:0.303821:0.011032:0.005200:0.004567:0.012486:0.015873:0.010947:0.004977:0.003250:0.010895:0.011682
. 2000;6(Suppl 1):S11-S4.:@0.650722:0.317826:0.841333:0.317826:0.841333:0.303821:0.650722:0.303821:0.004567:0.004567:0.009305:0.009305:0.009305:0.009305:0.004567:0.009305:0.006140:0.008347:0.010228:0.011494:0.011494:0.003250:0.004567:0.009305:0.006140:0.004567:0.008347:0.009305:0.009305:0.005508:0.008347:0.009305:0.004738
10.  Chapman PB, Hauschild A, Robert C, :@0.523636:0.333772:0.872394:0.333772:0.872394:0.319767:0.523636:0.319767:0.009476:0.009476:0.004738:0.012657:0.000000:0.013906:0.010434:0.011682:0.011665:0.016044:0.011682:0.010434:0.005063:0.010126:0.009818:0.004738:0.005063:0.011682:0.011682:0.010399:0.006636:0.011067:0.010434:0.003421:0.003421:0.011716:0.005080:0.012657:0.004738:0.005063:0.010382:0.011203:0.011665:0.011118:0.005148:0.005798:0.005063:0.013906:0.004738:0.121773
et al:@0.872719:0.333772:0.909801:0.333772:0.909801:0.319767:0.872719:0.319767:0.011118:0.005798:0.005063:0.011682:0.003421
.:@0.909801:0.333772:0.914539:0.333772:0.914539:0.319767:0.909801:0.319767:0.004738
Improved survival with vemurafenib in mel-:@0.559983:0.349718:0.914558:0.349718:0.914558:0.335712:0.559983:0.335712:0.003866:0.016044:0.011665:0.005082:0.011203:0.009476:0.011118:0.011716:0.004977:0.006636:0.010399:0.005148:0.009476:0.003421:0.009476:0.011682:0.003421:0.004977:0.014214:0.003421:0.005798:0.010434:0.004977:0.009476:0.011118:0.016044:0.010399:0.005148:0.011682:0.005371:0.011118:0.010434:0.003421:0.011665:0.004977:0.003421:0.010434:0.004977:0.016044:0.011118:0.003421:0.005679
anoma with BRAF V600E mutation. :@0.559983:0.365663:0.849307:0.365663:0.849307:0.351658:0.559983:0.351658:0.011682:0.010434:0.011203:0.016044:0.011682:0.004847:0.014214:0.003421:0.005798:0.010434:0.004849:0.009818:0.010382:0.012657:0.008296:0.004846:0.012007:0.009476:0.009476:0.009476:0.009168:0.004858:0.016044:0.010399:0.005798:0.011682:0.005798:0.003421:0.011203:0.010434:0.004738:0.004738
N Engl J:@0.849426:0.365663:0.914556:0.365663:0.914556:0.351658:0.849426:0.351658:0.012657:0.004846:0.009168:0.010434:0.011511:0.003421:0.004849:0.008244
Med:@0.559983:0.381609:0.598536:0.381609:0.598536:0.367603:0.559983:0.367603:0.015719:0.011118:0.011716
. 2011 364 2507 2516:@0.598536:0.381609:0.765338:0.381609:0.765338:0.367603:0.598536:0.367603:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004755:0.009476:0.009476:0.009476:0.009476:0.005696:0.009476:0.009476:0.009476:0.009476
;:@0.645915:0.381609:0.650653:0.381609:0.650653:0.367603:0.645915:0.367603:0.004738
::@0.679098:0.381609:0.683836:0.381609:0.683836:0.367603:0.679098:0.367603:0.004738
-:@0.721756:0.381609:0.727435:0.381609:0.727435:0.367603:0.721756:0.367603:0.005679
.:@0.765355:0.381609:0.770093:0.381609:0.770093:0.367603:0.765355:0.367603:0.004738
11.   Hauschild A, Grob J-J, Demidov LV, :@0.523653:0.397554:0.833333:0.397554:0.833333:0.383549:0.523653:0.383549:0.009479:0.009479:0.004731:0.004738:0.007919:0.000000:0.011169:0.011169:0.009886:0.006123:0.010553:0.009921:0.002908:0.002908:0.011203:0.003848:0.012144:0.004225:0.003848:0.014402:0.004567:0.010690:0.011152:0.003848:0.007731:0.005166:0.007731:0.004225:0.003848:0.012213:0.010605:0.015531:0.002908:0.011203:0.010690:0.008963:0.003848:0.005460:0.009683:0.004225:0.068060
et al:@0.832444:0.397554:0.866772:0.397554:0.866772:0.383549:0.832444:0.383549:0.010605:0.005285:0.003848:0.011169:0.003421
. Dab-:@0.866259:0.397554:0.914544:0.397554:0.914544:0.383549:0.866259:0.383549:0.004225:0.003848:0.012213:0.011169:0.011152:0.005679
rafenib in BRAF-mutated metastatic mela- :@0.560000:0.413500:0.919294:0.413500:0.919294:0.399494:0.560000:0.399494:0.004635:0.011169:0.004858:0.010605:0.009921:0.002908:0.011152:0.010861:0.002908:0.009921:0.010861:0.009305:0.009869:0.012144:0.007782:0.005166:0.015531:0.009886:0.005285:0.011169:0.005285:0.010605:0.011203:0.010861:0.015531:0.010605:0.005285:0.011169:0.006123:0.005285:0.011169:0.005285:0.002908:0.010553:0.010861:0.015531:0.010605:0.002908:0.011169:0.005679:0.004738
noma: a multicentre, open-label, phase  3:@0.560000:0.429445:0.914556:0.429445:0.914556:0.415440:0.560000:0.415440:0.009921:0.010690:0.015531:0.011169:0.004225:0.010126:0.011169:0.010126:0.015531:0.009886:0.002908:0.005285:0.002908:0.010553:0.010605:0.009921:0.005285:0.004563:0.010605:0.004225:0.010126:0.010690:0.011152:0.010605:0.009921:0.005166:0.002908:0.011169:0.011152:0.010605:0.002908:0.004225:0.010126:0.011152:0.009921:0.011169:0.006123:0.010608:0.004738:0.005388:-0.054812
randomised controlled trial:@0.560000:0.445391:0.788749:0.445391:0.788749:0.431386:0.560000:0.431386:0.005148:0.011682:0.010434:0.011716:0.011203:0.016044:0.003421:0.006636:0.011118:0.011716:0.007851:0.011067:0.011203:0.010434:0.005798:0.005075:0.011203:0.003421:0.003421:0.011118:0.011716:0.007851:0.005798:0.005148:0.003421:0.011682:0.003421
. Lancet. :@0.788749:0.445391:0.868814:0.445391:0.868814:0.431386:0.788749:0.431386:0.004738:0.007851:0.007902:0.011682:0.010434:0.011067:0.011118:0.005798:0.004738:0.004738
2012:@0.871915:0.445391:0.909819:0.445391:0.909819:0.431386:0.871915:0.431386:0.009476:0.009476:0.009476:0.009476
;:@0.909836:0.445391:0.914574:0.445391:0.914574:0.431386:0.909836:0.431386:0.004738
380 358 365:@0.560017:0.461336:0.655733:0.461336:0.655733:0.447331:0.560017:0.447331:0.009476:0.009476:0.009476:0.004755:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476
::@0.588462:0.461336:0.593200:0.461336:0.593200:0.447331:0.588462:0.447331:0.004738
-:@0.621627:0.461336:0.627306:0.461336:0.627306:0.447331:0.621627:0.447331:0.005679
.:@0.655750:0.461336:0.660488:0.461336:0.660488:0.447331:0.655750:0.447331:0.004738
12.  Robert  C,  Karaszewska  B,  Schacter  J, :@0.523671:0.477282:0.892984:0.477282:0.892984:0.463277:0.523671:0.463277:0.009476:0.009476:0.004738:0.012657:0.000000:0.010382:0.011203:0.011665:0.011118:0.005148:0.005798:0.004738:0.004687:0.013906:0.004738:0.004738:0.004690:0.010109:0.011682:0.005148:0.011682:0.006636:0.007269:0.011118:0.014214:0.006636:0.008586:0.011682:0.004738:0.004692:0.009818:0.004738:0.004738:0.004693:0.008518:0.011067:0.010434:0.011682:0.011067:0.005798:0.011118:0.005148:0.004738:0.004685:0.008244:0.004738:0.004738
et:@0.897674:0.477282:0.914591:0.477282:0.914591:0.463277:0.897674:0.463277:0.011118:0.005798
al:@0.560017:0.493228:0.575120:0.493228:0.575120:0.479222:0.560017:0.479222:0.011682:0.003421
.  Three-year  estimate  of  overall survival:@0.575120:0.493228:0.914570:0.493228:0.914570:0.479222:0.575120:0.479222:0.004738:0.004738:0.003973:0.007286:0.010434:0.005075:0.011118:0.011118:0.005679:0.009168:0.011118:0.011682:0.005148:0.004738:0.003972:0.011118:0.006636:0.005798:0.003421:0.016044:0.011682:0.005798:0.011118:0.004738:0.003977:0.011203:0.005371:0.004738:0.003970:0.011203:0.009476:0.011118:0.005148:0.011682:0.003421:0.003421:0.008723:0.006636:0.010399:0.005148:0.009476:0.003421:0.009476:0.011682:0.003421
in COMBI-v, a randomized  phase 3 study:@0.560017:0.509173:0.914582:0.509173:0.914582:0.495168:0.560017:0.495168:0.003421:0.010434:0.007748:0.013906:0.014864:0.015719:0.009818:0.003866:0.005679:0.009476:0.004738:0.007748:0.011682:0.007748:0.005148:0.011682:0.010434:0.011716:0.011203:0.016044:0.003421:0.007269:0.011118:0.011716:0.004738:0.003002:0.011665:0.010434:0.011682:0.006636:0.011118:0.007748:0.009476:0.007748:0.006636:0.005798:0.010399:0.011716:0.009168
evaluating first-line dabrafenib + trametinib:@0.560017:0.525119:0.914580:0.525119:0.914580:0.511113:0.560017:0.511113:0.011118:0.009476:0.011682:0.003421:0.010399:0.011682:0.005798:0.003421:0.010434:0.011511:0.004211:0.004165:0.004165:0.005148:0.006636:0.005798:0.005679:0.003421:0.003421:0.010434:0.011118:0.004206:0.011716:0.011682:0.011665:0.005148:0.011682:0.005371:0.011118:0.010434:0.003421:0.011665:0.004213:0.010365:0.004208:0.005798:0.005148:0.011682:0.016044:0.011118:0.005798:0.003421:0.010434:0.003421:0.011665
in patients with unresectable or metastatic:@0.560017:0.541064:0.914587:0.541064:0.914587:0.527059:0.560017:0.527059:0.003421:0.010434:0.005080:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.005071:0.014214:0.003421:0.005798:0.010434:0.005071:0.010399:0.010434:0.005073:0.011118:0.006636:0.011118:0.011067:0.005798:0.011682:0.011665:0.003421:0.011118:0.005080:0.011203:0.005148:0.005066:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067
BRAF V600E/K-mutant cutaneous  mela-:@0.560017:0.557010:0.914579:0.557010:0.914579:0.543004:0.560017:0.543004:0.009818:0.010382:0.012657:0.008296:0.014573:0.012007:0.009476:0.009476:0.009476:0.009168:0.007475:0.010109:0.005679:0.016044:0.010399:0.005798:0.011682:0.010434:0.005798:0.014573:0.011067:0.010399:0.005798:0.011682:0.010434:0.011118:0.011203:0.010399:0.006636:0.004738:0.009823:0.016044:0.011118:0.003421:0.011682:0.005679
nom. Presented at the 2016 European So-:@0.560017:0.572955:0.914599:0.572955:0.914599:0.558950:0.560017:0.558950:0.010434:0.011203:0.016044:0.004738:0.006688:0.010126:0.005075:0.011118:0.006636:0.011118:0.010434:0.005798:0.011118:0.011716:0.006688:0.011682:0.005798:0.006688:0.005798:0.010434:0.011118:0.006688:0.009476:0.009476:0.009476:0.009476:0.006703:0.009168:0.010399:0.005078:0.011203:0.011665:0.011118:0.011682:0.010434:0.006688:0.008518:0.011203:0.005679
ciety for Medical Oncology meeting.:@0.560017:0.588901:0.866459:0.588901:0.866459:0.574896:0.560017:0.574896:0.011067:0.003421:0.011118:0.005798:0.009168:0.004738:0.005371:0.011203:0.005148:0.004738:0.015719:0.011118:0.011716:0.003421:0.011067:0.011682:0.003421:0.004738:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738:0.016044:0.011118:0.011118:0.005798:0.003421:0.010434:0.011511:0.004738